The Experts below are selected from a list of 147 Experts worldwide ranked by ideXlab platform
Jun Shimazaki - One of the best experts on this subject based on the ideXlab platform.
-
antiandrogen withdrawal syndrome in prostate cancer after treatment with steroidal antiandrogen Chlormadinone Acetate
Urology, 1995Co-Authors: Koichiro Akakura, Susumu Akimoto, Takemasa Ohki, Jun ShimazakiAbstract:Abstract Objectives A case report is presented of 2 patients whose levels of serum prostate-specific antigen (PSA) improved after the withdrawal of a steroidal antiandrogen. Methods Two cases with prostate cancer had been treated with surgical castration and the steroidal antiandrogen Chlormadinone Acetate (CMA), and, on disease progression, the administration of CMA was terminated. Results Following withdrawal of CMA, a fall in PSA levels and remarkable clinical improvement were observed in both cases. One patient revealed a decrease and the other an increase in serum prostate acid phosphatase after the discontinuation of CMA. Serum levels of testosterone, prolactin, dehydroepiandrosterone, dehydroepiandrosterone sulfate, and androstenedione were not significantly elevated after CMA withdrawal. Conclusions Withdrawal of the steroidal antiandrogen CMA resulted in a decline in PSA levels and clinical improvement in prostate cancer patients with disease progression. Changes in testosterone, prolactin, or adrenal androgens were not a cause of the antiandrogen withdrawal syndrome.
Megumi Sonohara - One of the best experts on this subject based on the ideXlab platform.
-
clinical utility of Chlormadinone Acetate lutoral in frozen thawed embryo transfer with hormone replacement
Reproductive Medicine and Biology, 2019Co-Authors: Yoshimasa Asada, Yoshiki Hashiba, Yukio Hattori, Daichi Inoue, Rie Ito, Noritaka Fukunaga, Megumi SonoharaAbstract:Purpose The clinical utility of Chlormadinone Acetate tablets (Lutoral™), an orally active progestin which has been available since June 2007, was compared to an in-house vaginal suppository formulation of progesterone used between 2006 and 2007 for assisted reproductive technology (ART). Methods We retrospectively evaluated the efficacy and safety of Chlormadinone Acetate by comparing the pregnancy rates and the incidences of birth defects and hypospadias in frozen-thawed embryo transfer cycles using the in-house vaginal progesterone and those using Chlormadinone Acetate for luteal phase support. Results The pregnancy rates in the frozen-thawed embryo transfer cycles were 31.2% (259/831) with vaginal progesterone for luteal phase support and 31.6% (4228/13 381) with Chlormadinone Acetate (no significant difference). In the cycles resulting in live birth following administration of Chlormadinone Acetate between July 2007 and December 2015, the incidence of birth defects was 2.8% (80/2893), and the incidence of hypospadias was 0.03% (1/2893). Conclusions These results indicate that the pregnancy rate following frozen-thawed embryo transfer using Chlormadinone Acetate for luteal phase support was comparable with that using vaginal progesterone, with no increased risk of birth defects, including hypospadias, which has been a concern following the use of progestins.
-
Clinical utility of Chlormadinone Acetate (Lutoral™) in frozen-thawed embryo transfer with hormone replacement.
Reproductive medicine and biology, 2019Co-Authors: Yoshimasa Asada, Yoshiki Hashiba, Yukio Hattori, Daichi Inoue, Rie Ito, Noritaka Fukunaga, Megumi SonoharaAbstract:The clinical utility of Chlormadinone Acetate tablets (Lutoral™), an orally active progestin which has been available since June 2007, was compared to an in-house vaginal suppository formulation of progesterone used between 2006 and 2007 for assisted reproductive technology (ART). We retrospectively evaluated the efficacy and safety of Chlormadinone Acetate by comparing the pregnancy rates and the incidences of birth defects and hypospadias in frozen-thawed embryo transfer cycles using the in-house vaginal progesterone and those using Chlormadinone Acetate for luteal phase support. The pregnancy rates in the frozen-thawed embryo transfer cycles were 31.2% (259/831) with vaginal progesterone for luteal phase support and 31.6% (4228/13 381) with Chlormadinone Acetate (no significant difference). In the cycles resulting in live birth following administration of Chlormadinone Acetate between July 2007 and December 2015, the incidence of birth defects was 2.8% (80/2893), and the incidence of hypospadias was 0.03% (1/2893). These results indicate that the pregnancy rate following frozen-thawed embryo transfer using Chlormadinone Acetate for luteal phase support was comparable with that using vaginal progesterone, with no increased risk of birth defects, including hypospadias, which has been a concern following the use of progestins.
Koichiro Akakura - One of the best experts on this subject based on the ideXlab platform.
-
antiandrogen withdrawal syndrome in prostate cancer after treatment with steroidal antiandrogen Chlormadinone Acetate
Urology, 1995Co-Authors: Koichiro Akakura, Susumu Akimoto, Takemasa Ohki, Jun ShimazakiAbstract:Abstract Objectives A case report is presented of 2 patients whose levels of serum prostate-specific antigen (PSA) improved after the withdrawal of a steroidal antiandrogen. Methods Two cases with prostate cancer had been treated with surgical castration and the steroidal antiandrogen Chlormadinone Acetate (CMA), and, on disease progression, the administration of CMA was terminated. Results Following withdrawal of CMA, a fall in PSA levels and remarkable clinical improvement were observed in both cases. One patient revealed a decrease and the other an increase in serum prostate acid phosphatase after the discontinuation of CMA. Serum levels of testosterone, prolactin, dehydroepiandrosterone, dehydroepiandrosterone sulfate, and androstenedione were not significantly elevated after CMA withdrawal. Conclusions Withdrawal of the steroidal antiandrogen CMA resulted in a decline in PSA levels and clinical improvement in prostate cancer patients with disease progression. Changes in testosterone, prolactin, or adrenal androgens were not a cause of the antiandrogen withdrawal syndrome.
Hervé Galons - One of the best experts on this subject based on the ideXlab platform.
-
Development of a new sensitive and specific time-resolved fluoroimmunoassay (TR-FIA) of Chlormadinone Acetate in the serum of treated menopausal women.
Steroids, 2002Co-Authors: Jean Fiet, Frank Giton, Jack Auzerie, Hervé GalonsAbstract:We describe the development of a serum Chlormadinone Acetate (CMA) time-resolved fluoroimmunoassay (TR-FIA). We prepared haptens (3-CMO-Chlormadinone Acetate and 6-chloropregna-4,6-dien-17,20-diol-3-one-20-hemisuccinate), biotinylated tracers (3(biotinylaminopropylamido) 3-CMO-Chlormadinone Acetate and 3-(6-chloropregna-4,6-dien-17,20-diol-3-one-20-hemisuccinylamino)1-biotinylaminopropane), and immunogens necessary for eliciting two antibodies (anti-Chlormadinone Acetate 3-CMO/BSA and anti-Chlormadinone 20-hemisuccinate/BSA). The specificity of the assay was rigorously studied to eliminate possible interference by polar metabolites of CMA, particularly 17 alpha-acetoxy-6-chloro-3beta-hydroxypregna-4,6-diene-20-one (3beta-hydroxy metabolite), employing an easy-to-use ethylene glycol chromatographic step prior to immunoassay, so as to separate the polar metabolites, in particular the 3beta-hydroxy-CMA metabolite, from the intact CMA. The choice of the anti-CMA antibody was guided by the high assay sensitivity obtained with the anti-CMA 3-CMO/BSA antibody. The detection limit was 51pg/ml. Interassay reproducibility CVs were between 2.6 and 4.5%. This TR-FIA thus appeared to be a sensitive, specific, precise, and consequently well-suited method for measurement of serum CMA during a pharmacokinetic study in women.
Kenkichi Koiso - One of the best experts on this subject based on the ideXlab platform.
-
Chlormadinone Acetate Withdrawal Syndrome under Combined Androgen Blockade for Advanced Prostate Cancer
Japanese journal of clinical oncology, 1995Co-Authors: Noritoshi Sekido, Koji Kawai, Hideyuki Akaza, Kenkichi KoisoAbstract:Between July 1991 and December 1994 at Tsukuba Gakuen Hospital, we treated 19 consecutive men with advanced adenocarcinoma of the prostate (five at stage C, four at stage D1 and 10 at stage D2). Of these, 14 patients underwent castration (two patients) or received LH-RH analogue (12 patients) plus Chlormadinone Acetate for combined androgen blockade. We report three representative cases of sequential prostate specific antigen (PSA) elevation following initial response to this combined androgen blockade. Discontinuation of Chlormadinone Acetate resulted in decline of the serum PSA level. This suggests that trial Chlormadinone Acetate withdrawal in patients showing increasing levels of PSA during combined androgen blockade should be considered before initiation of alternative treatment.